Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

A Study to Assess the Effects of an Oral Dietary Supplement on Overall Facial Appearance Among Healthy Adult Women With Existing Skin Damage From Sun Exposure

Phase 4

Completed

Conditions: Photodamaged Skin

Interventions: Dietary Supplement: Placebo
Dietary Supplement: Imedeen

First Posted Date: 2013-02-08

Last Posted Date: 2015-03-18

Lead Sponsor: Pfizer

Target Recruit Count: 194

Registration Number: NCT01787461

Locations: 🇺🇸
TKL Research, Inc., Fair Lawn, New Jersey, United States
🇺🇸
Baumann Cosmetic and Research Institute, Miami, Florida, United States
🇺🇸
McDaniel Institute of Anti-Aging Research, Virginia Beach, Virginia, United States

and more 1 locations

Special Investigation Of Azithromycin IV For Legionnaires' Disease (Regulatory Post Marketing Commitment Plan)

Completed

Conditions: Legionnaires' Disease
Legionella Pneumophila Infections

Interventions: Drug: Azithromycin IV

First Posted Date: 2013-02-06

Last Posted Date: 2017-11-30

Lead Sponsor: Pfizer

Target Recruit Count: 21

Registration Number: NCT01784770

Study of Etanercept in Subjects With Rheumatoid Arthritis Who Have Had an Inadequate Response to Adalimumab or Infliximab Plus Methotrexate

Phase 4

Terminated

Conditions: Rheumatoid Arthritis

Interventions: Drug: Etanercept
Drug: Placebo

First Posted Date: 2013-02-04

Last Posted Date: 2016-01-06

Lead Sponsor: Pfizer

Target Recruit Count: 16

Registration Number: NCT01783015

Locations: 🇦🇺
RK Will Pty Ltd, Victoria Park, Western Australia, Australia
🇫🇷
Hopital Lapeyronie, Montpellier, France
🇷🇺
LLC "Alliance Biomedical - Russian Group", Izhevsk, Russian Federation

and more 11 locations

A Post Marketing Surveillance As Required By Philippine Food And Drug Administration

Withdrawn

Conditions: Renal Cell Carcinoma

Interventions: Drug: Temsirolimus

First Posted Date: 2013-02-01

Last Posted Date: 2013-05-01

Lead Sponsor: Pfizer

Registration Number: NCT01781442

A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma

Phase 1

Completed

Conditions: Locally Advanced or Metastatic NRAS Mutant Melanoma

Interventions: Drug: LEE011
Drug: MEK162

First Posted Date: 2013-02-01

Last Posted Date: 2020-12-07

Lead Sponsor: Pfizer

Target Recruit Count: 102

Registration Number: NCT01781572

Locations: 🇳🇱
Pfizer Investigative Site 1150, Nijmegen, Netherlands
🇩🇪
Pfizer Investigative Site 1053, Gera, Germany
🇺🇸
Columbia University Medical Center- New York Presbyterian Onc Dept., New York, New York, United States

and more 14 locations

AStudy To Evaluate Safety And Eficacy Of Apixaban In Japanese Acute Deep Vein Thrombosis (DVT) And Pulmonary Embolism (PE) Patients

Phase 3

Completed

Conditions: Deep Vein Thrombosis
Pulmonary Embolism

Interventions: Drug: Unfractionated Heparin (UFH)
Drug: Apixaban
Drug: Warfarin

First Posted Date: 2013-01-31

Last Posted Date: 2016-06-23

Lead Sponsor: Pfizer

Target Recruit Count: 80

Registration Number: NCT01780987

Locations: 🇯🇵
Toho University Sakura Medical Center, Sakura, Chiba, Japan
🇯🇵
Kokura Memorial Hospital, Kitakyusyu, Fukuoka, Japan
🇯🇵
National Cerebral and Cardiovascular Center Hospital, Suita-shi, Osaka, Japan

and more 17 locations

Safety and Tolerability Study of Multiple Doses of PF-06305591

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: PF-06305591
Drug: Placebo

First Posted Date: 2013-01-28

Last Posted Date: 2013-12-03

Lead Sponsor: Pfizer

Target Recruit Count: 43

Registration Number: NCT01776619

Locations: 🇧🇪
Pfizer Investigational Site, Brussels, Belgium

Study of BMN 673, a PARP Inhibitor, in Healthy Adult Male Volunteers

Phase 1

Completed

Conditions: Human Volunteers

Interventions: Drug: BMN 673

First Posted Date: 2013-01-28

Last Posted Date: 2017-07-28

Lead Sponsor: Pfizer

Target Recruit Count: 18

Registration Number: NCT01776437

Locations: 🇺🇸
Covance Clinical Research Unit Inc., Evansville, Indiana, United States

A Study To Determine Any Effect Of Tafamidis On Electrocardiographic Intervals, Specifically The Rate Corrected QT Interval (QTc)

Phase 1

Completed

Conditions: TTR Cardiomyopathy

Interventions: Drug: Period 1
Drug: Period 2
Drug: Period 3

First Posted Date: 2013-01-25

Last Posted Date: 2013-05-21

Lead Sponsor: Pfizer

Target Recruit Count: 42

Registration Number: NCT01775761

Locations: 🇸🇬
Pfizer Investigational Site, Singapore, Singapore

ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.

Phase 3

Completed

Conditions: Non-small Cell Lung Cancer With EGFR-Activating Mutations

Interventions: Drug: Dacomitinib (PF-00299804)
Drug: Gefitinib

First Posted Date: 2013-01-24

Last Posted Date: 2023-11-14

Lead Sponsor: Pfizer

Target Recruit Count: 452

Registration Number: NCT01774721

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy